Direct oHSV Infection Induces DC Maturation and a Tumor Therapeutic Response
Open Access
Abstract
Oncolytic herpes simplex virus (oHSV) is a promising cancer immunotherapy that induces tumor cell lysis and stimulates anti-tumor immunity. Our previous single-cell RNA sequencing analysis of oHSV-treated medulloblastoma tumors revealed expansion and activation of tumor-infiltrating dendritic cells (DCs), and direct oHSV infection of DCs within the brain. While the therapeutic effects of oHSVs have been primarily attributed to tumor cell infection, we hypothesize that direct infection of DCs also contributes to therapeutic efficacy by promoting DC maturation and immune activation. Although the oHSV infection in DCs was abortive, it led to increased expression of major histocompatibility complex (MHC) class I/II and co-stimulatory molecules. oHSV-infected DCs activated naïve CD4+ and CD8+ T cells, inducing expression of CD69 and CD25. These primed T cells exhibited enhanced cytotoxicity against CT-2A glioma cells. Adoptive transfer of oHSV-infected DCs via subcutaneous injection near inguinal lymph nodes delayed tumor growth in a syngeneic CT-2A glioma model, independent of tumor viral replication and lysis. Mechanistically, our in vitro studies demonstrate that oHSV can directly infect and functionally activate DCs, enabling them to prime effective anti-tumor T cell responses. This study highlights the anti-tumor potential of leveraging oHSV-infected DCs to augment viroimmunotherapy as a cancer therapeutic.Keywords
Funding Information
- CancerFree KIDS (AWD50001350, W81XWH2010340, U54-CA232561)
- Department of Defense (AWD50001350, W81XWH2010340, U54-CA232561)
- NIH (AWD50001350, W81XWH2010340, U54-CA232561)
This publication has 52 references indexed in Scilit:
- Rodent models of tumours of the central nervous systemMolecular Oncology, 2024
- Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastomaTranslational Oncology, 2024
- Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolutionMolecular Therapy-Oncolytics, 2023
- Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitmentMolecular Therapy-Oncolytics, 2021
- Pre-clinical tumor models of primary brain tumors: Challenges and opportunitiesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic VirotherapiesTrends in Immunology, 2018
- Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memoryTranslational Oncology, 2018
- Oncolytic Virotherapy for the Treatment of Malignant GliomaNeurotherapeutics, 2017
- Glioma: experimental models and realityActa Neuropathologica, 2017
- Tumor Growth Inhibition by Intratumoral Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte–Macrophage Colony-Stimulating FactorMolecular Therapy, 2000